Home/ Stocks/ SKYE

Skye Bioscience, Inc. Common Stock

SKYE XNAS

$0.52 +0.04 (+8.98%) ▲ 15-min delayed

Open

$0.49

High

$0.54

Low

$0.47

Volume

335.3K

Market Cap

$16.58M

About Skye Bioscience, Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 12 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-12,509,361	$-0.32
FY 2025	$0	$-55,924,814	$-1.41
Q3 2025	$0	$-12,754,660	$-0.32
Q2 2025	$0	$-17,624,872	$-0.44

Related Market News

No specific coverage for SKYE yet. Check out our latest market news or earnings calendar.

Get SKYE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Skye Bioscience, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.